First experience on the effect of in-feed lincomycin for the control of proliferative enteropathy in growing pigs

J Vet Med A Physiol Pathol Clin Med. 2006 Apr;53(3):157-62. doi: 10.1111/j.1439-0442.2006.00803.x.

Abstract

This trial's aim was to evaluate the effect of in-feed lincomycin for the control of proliferative enteropathy (PE; also known as ileitis) in growing pigs, in which it is associated with significant morbidity levels. Investigation regarding the efficacy of this substance in growing pigs has never been carried out before in a field trial. The trial farm had a previous history of PE outbreaks. On day 1 of the trial (age of 62 +/- 1.5 days), 240 pigs were divided into two groups of 120 pigs/group which were allocated into five pens of 24 pigs each. Therefore, a randomized block design was used with two experimental groups (T1-T2) and five replicates (pens) per group. T1 group served as negative control (NC) animals which were receiving no medication and conversely T2 group received in-feed lincomycin at the dose of 110 mg/kg of feed. The treatment period lasted for 3 weeks, followed by an observation period of 4 weeks up to the age of 111 +/- 1.5 days which was the end of the grower stage. Administration of lincomycin at a dose of 110 mg/kg of feed had beneficial effects compared with the NC group. The pigs of T2 group showed significant improvement of their production parameters in terms of average daily body gain (ADG) and feed conversion ratio (FCR) not only during the treatment period (ADG: 0.515 +/- 0.050 versus 0.481 +/- 0.071 and FCR: 2.38 +/- 0.05 versus 2.56 +/- 0.08, for T2 and T1 groups respectively), but also during the remaining period until the end of the grower stage (observation period: ADG: 0.687 +/- 0.019 versus 0.646 +/- 0.044 and FCR: 2.58 +/- 0.02 versus 2.74 +/- 0.02 respectively). Other effects in the T2 group refer to the reduction of diarrhoea prevalence (mean pen diarrhoea score during the whole grower stage: 0.200 +/- 0.060 versus 0.632 +/- 0.041 respectively), morbidity rates (morbidity rates during the whole grower stage: 15.83% versus 45.00% respectively) and the reduction of Lawsonia intracellularis prevalence as shown by polymerase chain reaction diagnostic method (at the end of the treatment period: 10.0% versus 60.0% respectively). In conclusion, treatment with 110 mg lincomycin/kg of feed for 21 consecutive days had a beneficial effect on the control of PE in growing pigs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animal Feed
  • Animals
  • Animals, Newborn
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Desulfovibrionaceae Infections / prevention & control
  • Desulfovibrionaceae Infections / veterinary*
  • Feces / microbiology
  • Female
  • Ileitis / prevention & control
  • Ileitis / veterinary*
  • Lawsonia Bacteria* / drug effects
  • Lawsonia Bacteria* / genetics
  • Lawsonia Bacteria* / isolation & purification
  • Lincomycin / pharmacology
  • Lincomycin / therapeutic use*
  • Male
  • Polymerase Chain Reaction / veterinary
  • Random Allocation
  • Swine
  • Swine Diseases / prevention & control*
  • Treatment Outcome
  • Weight Gain / drug effects

Substances

  • Anti-Bacterial Agents
  • Lincomycin